(News Bulletin 247) – Transgene, a biotechnology company that designs and develops immunotherapies based on viral vectors against cancers, and NEC Corporation, a leader in information technologies, networks and artificial intelligence (AI) , announce the presentation of new data on TG4050, an individualized neoantigenic vaccine at the annual meeting of the American Society of Clinical Oncology (ASCO 2023) in Chicago (USA).
TG4050 comes from Transgene’s myvac ® platform and benefits from NEC’s Artificial Intelligence (AI) technologies.
The new positive data was generated in patients with HPV-negative head and neck cancers treated in a Phase I trial currently evaluating TG4050 (NCT04183166). All patients treated with TG4050 in this trial developed a specific immune response, as demonstrated by the results of complementary immunological analyses, and are still in remission to date.
Alessandro Riva, Chairman and CEO of Transgene, said: ‘TG4050 is demonstrating its potential to prolong patients’ remission after surgery and thus positions Transgene among the pioneers in the emerging field of individualized cancer vaccines. The monotherapy data we are presenting at ASCO provides a solid foundation to accelerate the clinical development of this innovative therapy as an adjuvant treatment for HPV-negative head and neck carcinoma and potentially in other indications. ‘
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
